Beam Therapeutics (BEAM) Gains from Investment Securities (2024 - 2026)

Beam Therapeutics (BEAM) has reported Gains from Investment Securities for 3 consecutive years, with -$514000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 2003.7% year-over-year to -$514000.0; the TTM figure through Mar 2026 stood at -$721000.0 (up 57.54% YoY), while the FY2025 annual figure was -$180000.0, up 88.69% from the prior year.
• Gains from Investment Securities slipped to -$514000.0 in Q1 2026 per BEAM's latest filing, from $765000.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $765000.0 in Q4 2025 and bottomed at -$1.8 million in Q2 2024.
• Historically, Gains from Investment Securities has averaged -$254000.0 across 3 years, with a median of $27000.0 in 2024.
• On a YoY basis, Gains from Investment Securities climbed as much as 2733.33% in 2025 and fell as far as 3803.7% in 2025.
• Beam Therapeutics' Gains from Investment Securities stood at $27000.0 in 2024, then soared by 2733.33% to $765000.0 in 2025, then tumbled by 167.19% to -$514000.0 in 2026.
• Business Quant data shows BEAM's Gains from Investment Securities at -$514000.0 in Q1 2026, $765000.0 in Q4 2025, and -$1.0 million in Q3 2025.